Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 5/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 2/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7753657 | 0.75 | CHRNB2 (0.70) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 | |
| SCHEMBL7759608 | 0.75 | CHRNB2 (0.70) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 | |
| SCHEMBL7756327 | 0.75 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 | |
| SCHEMBL7756342 | 0.74 | CHRNA3 (0.71) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 | |
| SCHEMBL7753648 | 0.74 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 | |
| SCHEMBL7955933 | 0.74 | CHRNB2 (0.58) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 | |
| Hydrochloric Acid SCHEMBL7757792 | 0.74 | CHRNB2 (0.68) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 | |
| Hydrochloric Acid SCHEMBL7753623 | 0.73 | CHRNA3 (0.69) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 | |
| SCHEMBL7757357 | 0.72 | CHRNB2 (0.56) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 | |
| SCHEMBL5937716 | 0.71 | CHRNB2 (0.55) | CHRNB2CHRNA3CHRNA4CHRNA7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20250078957-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250022541-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240428948-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4479973-A1 | UNSUPERVISED MACHINE LEARNING METHODS | Ampel Biosolutions, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2024-09-26 | — | — | US | disclosed |
| WO-2023158713-A1 | UNSUPERVISED MACHINE LEARNING METHODS | AMPEL BIOSOLUTIONS, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2001049690-A1 | 9-AZABICYCLO[4.2.1]NON-2-ENE DERIVATIVES AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF BRISTOL (GB) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CHRNB2 1/4885CHRNA3 10/4885CHRNA4 15/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | CHRNB2 5/4885CHRNA3 9/4885CHRNA4 4/4885 |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CHRNB2 1/4885CHRNA3 10/4885CHRNA4 15/4885 |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CHRNB2 1/4885CHRNA3 10/4885CHRNA4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.